peramivir (Rapivab)
Jump to navigation
Jump to search
Introduction
FDA-approved Dec 2014
Indications
Dosage
- 600 mg intravenous infusion (once)
Adverse effects
Mechanism of action
- sialic acid analog, selective inhibitor of neuraminidases produced by influenza A virus & influenza B virus[2]
Notes
More general terms
References
- ↑ FDA MedWatch http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm187814.htm
- ↑ 2.0 2.1 Kohno S et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010 Nov; 54:4568 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20713668
- ↑ FDA News Release. December 22, 2014 FDA approves Rapivab to treat flu infection http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm
- ↑ Peramivir prescribing information http://rapivab.com/wp-content/uploads/2014/12/Rapivab-PI.pdf